June Issue Now Available

Oak Brook, IL (June 3, 2021) – The June edition of SLAS Discovery features the cover article, “A Perspective on Synthetic Biology in Drug Discovery and Development—Current Impact and Future Opportunities” by Florian David, Ph.D. (Chalmers University of Technology, Gothenburg, Sweden), Andrew M. Davis, Ph.D. (AstraZeneca, Cambridge, England, UK). Michael Gossing, Ph.D., Martin A. Hayes, Ph.D., and Elvira Romero, Ph.D., and Louis H. Scott, Ph.D. (AstraZeneca, Gothenburg, Sweden), and Mark J. Wigglesworth, Ph.D. (AstraZeneca, London, England, UK).

The June issue of SLAS Discovery includes nine articles of original research. These include:

• Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors
• In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform
• Identification and Kinetic Characterization of Serum- and Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence Polarization-Based Assay
• Reducing False Positives through the Application of Fluorescence Lifetime Technology: A Comparative Study Using TYK2 Kinase as a Model System
• Biochemical and Cellular Profile of NIK Inhibitors with Long Residence Times
• A Novel High-Throughput FLIPR Tetra-Based Method for Capturing Highly Confluent Kinetic Data for Structure–Kinetic Relationship Guided Early Drug Discovery
• A Multipronged Screening Approach Targeting Inhibition of ETV6 PNT Domain Polymerization
• Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines
• Regenerable Biosensors for Small-Molecule Kinetic Characterization Using SPR

Other articles include:

• A Perspective on Synthetic Biology in Drug Discovery and Development—Current Impact and Future Opportunities
• Public-Private Partnerships: Compound and Data Sharing in Drug Discovery and Development
• A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex Toward Developing Therapeutics for COVID-19
• Development of a High-Throughput Assay to Identify Inhibitors of ENPP1

Access to June’s SLAS Discovery issue is available at https://journals.sagepub.com/toc/jbxb/current. For more information about SLAS and its journals, visit https://www.slas.org/publications/slas-discovery/. Access a “behind the scenes” look at the latest issue with SLAS Discovery Author Insights podcast. Tune in by visiting https://www.buzzsprout.com/1099559.

*****

SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS Discovery: Advancing the Science of Drug Discovery, 2019 Impact Factor 2.195. Editor-in-Chief Robert M. Campbell, Ph.D., Twentyeight-Seven Therapeutics, Boston, MA (USA).

SLAS Technology: Translating Life Sciences Innovation, 2019 Impact Factor 2.174. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).

###